1,721,033 research outputs found
Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al
No full text
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
No full textA relatively large body of evidence supports the notion that glomerular capillary wall and mesangial alterations in diabetic nephropathy involve biochemical alterations of glycoproteins in these structures. Evidence in experimental animals rendered diabetic reveals that the administration of heparin and other anionic glycoproteins can effectively prevent the biochemical alterations that promote albuminuria. Moreover, angiotensin II inhibits heparan sulfate synthesis, while heparins modulate angiotensin II signaling in glomerular cells, inhibiting aldosterone synthesis and lowering proteinuria in diabetes patients. Sulodexide, a mixture of heparin and dermatan sulfate, appears to be a promising treatment for diabetic proteinuria partially resistant to renin-angiotensin system blocking agents. Sulodexide prevents heparan sulfate degradation, thus allowing reconstruction of heparan sulfate content and restoration of glomerular basement membrane ionic permselectivity. The antiproteinuric effect appears to be mainly related to the basal proteinuria and consequently to the duration of treatment in a relatively large number of small clinical trials. On the other hand, several sulodexide pharmacodynamic properties could improve the prognosis of chronic kidney disease patients, also independently from its antiproteinuric effect. However, sulodexide development as an antiproteinuric drug needs to be continued, in order to define which kind of patients could better respond to this treatment
Efficacy of soluble fiber supplementation in CV disease risk management of patients with metabolic syndrome: A 6-months, randomized clinical trial
No full textCombining natural treatments to reach lipid target in metabolic syndrome patients: A randomized clinical trial
No full textObjective: To invostigato whothor combinod thorapy with omoga-3 FA + policosanol offors bonofits compared with omoga-3 FA + placobo with rospoct to tho lipid profilo of pationts with mild Motabolic Syndromo(MS) in primary provontion.
Methods: This randomisod, double-blind study was conductod in 40 patients with MS, as dofinod by tho ATP III. After 4 wooks on a standardized AHA step 2 diet, pationts were randomisod to omoga-3 FA 2g/dio + placobo or
omoga-3 FA + policosanol 10 mg/day for 8 wooks. Omoga-3 FA was suppliod as lg capsulos (2 pot day); placobo and policosanol were providod in tablot form.
Results: After 8 weeks, omega-3 FA + policosanol, but not omega-3 FA + placebo, significantly reduced LDL-C by 22.94-3.8% (p<0.0001).
Omega-3 FA + policosanol significantly decreased LDL-C (26.34-3.4%; p<0.001) and TG (23.15.4-5.1%; p<0.005), and significantly increased HDLC (+10.24-2.8%; p<0.0001). Omega-3 FA + placebo significantly reduced
TG (21.24-6.8%; p<0.05) but had no significant effect on other lipid profile variables. The proportion of randomised patients in the omega-3 FA + policosanol group that achieved LDL-C targets was significantly greater than in
the omega-3 FA + placebo group (42% vs. 19%; p<0.001).
Conclusions: Treatment with omega-3 FA + policosanol could be useful for regulating lipid profile in patients with type Metabolic Syndrome in primary prevention.
Fundings: Alma Mater Studiorum University of Bologna, National Institute for Cardiovascular Research (INRC)
Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome.
No full textCombining natural treatments to reach lipid target in metabolic syndrome patients: A randomized clinical trial
No full text
- …
